TOP TEN perturbations for 38940_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38940_at
Selected probe(set): 209891_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38940_at (209891_at) across 6674 perturbations tested by GENEVESTIGATOR:
dengue fever study 10 (DHF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):6.151343Number of Samples:2 / 5
| Experimental | dengue fever study 10 (DHF) |
| Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis. | |
| Control | normal naive CD8 T cell sample |
| Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
dengue fever study 10 (DF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):5.9732776Number of Samples:3 / 5
| Experimental | dengue fever study 10 (DF) |
| Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. | |
| Control | normal naive CD8 T cell sample |
| Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector) / flagellin study 4 (control vector; 500 ng/ml)
Relative Expression (log2-ratio):-5.3595343Number of Samples:6 / 2
| Experimental | nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector) |
| Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with nutlin-3 (10 uM) for 45 hours followed by an additional 3 hours treatment of nutlin-3 (10uM) and flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. ATC code:--- | |
| Control | flagellin study 4 (control vector; 500 ng/ml) |
| Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with DMSO 0.1% for 45 hours followed by an additional 3 hours with flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. |
PD-0332991 study 4 (G1 arrest) / medium treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-5.3572946Number of Samples:3 / 3
| Experimental | PD-0332991 study 4 (G1 arrest) |
| Bronchial epithelial cells (NHBE) treated with CDK4/6 inhibitor PD-0332991 (palbociclib) to arrest them in G1 phase for 8 hours. Therefore, cells were cultured in standard growth medium for 24 hours, followed by treatment with 1 μM PD-0332991 (non-toxic dose) for another 24 hours and then washed and treated with the same dose of PD-0332991 again for indicated timepoints. ATC code:--- | |
| Control | medium treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) cultured in standard growth medium for 2 x 24 hours, followed by culture in growth medium for another 8 hours. |
nutlin-3 study 2 (control vector; 10uM) / vehicle treated MCF-7-con cell sample
Relative Expression (log2-ratio):-5.315116Number of Samples:6 / 3
| Experimental | nutlin-3 study 2 (control vector; 10uM) |
| Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with nutlin-3 (10 uM) for 48 hours. Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. ATC code:--- | |
| Control | vehicle treated MCF-7-con cell sample |
| Human breast adenocarcinoma cells MCF-7 expressing wild type p53 stably transfected with control empty vector pSUPER, vehicle treated with DMSO (0.1%) for 48 hours. Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. |
PD-0332991 study 3 (G1 arrest) / medium treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-5.174475Number of Samples:3 / 3
| Experimental | PD-0332991 study 3 (G1 arrest) |
| Bronchial epithelial cells (NHBE) treated with CDK4/6 inhibitor PD-0332991 (palbociclib) to arrest them in G1 phase for 6 hours. Therefore, cells were cultured in standard growth medium for 24 hours, followed by treatment with 1 μM PD-0332991 (non-toxic dose) for another 24 hours and then washed and treated with the same dose of PD-0332991 again for indicated timepoints. ATC code:--- | |
| Control | medium treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) cultured in standard growth medium for 2 x 24 hours, followed by culture in growth medium for another 6 hours. |
PD-0332991 study 1 (G1 arrest) / medium treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-5.084043Number of Samples:3 / 3
| Experimental | PD-0332991 study 1 (G1 arrest) |
| Bronchial epithelial cells (NHBE) treated with CDK4/6 inhibitor PD-0332991 (palbociclib) to arrest them in G1 phase for 2 hours. Therefore, cells were cultured in standard growth medium for 24 hours, followed by treatment with 1 μM PD-0332991 (non-toxic dose) for another 24 hours and then washed and treated with the same dose of PD-0332991 again for indicated timepoints. ATC code:--- | |
| Control | medium treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) cultured in standard growth medium for 2 x 24 hours, followed by culture in growth medium for another 2 hours. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):-5.051732Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
PD-0332991 study 1 (cell cycle re-entry) / medium treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-4.8636174Number of Samples:3 / 3
| Experimental | PD-0332991 study 1 (cell cycle re-entry) |
| Bronchial epithelial cells (NHBE) treated with CDK4/6 inhibitor PD-0332991 (palbociclib) to arrest them in G1 phase but then re-cultured in growth medium for 2 hours to selectively allow them re-entry of cell cycle. Therefore, cells were cultured in standard growth medium for 24 hours, followed by treatment with 1 μM PD-0332991 (non-toxic dose) for another 24 hours and then washed and treated with growth medium again for indicated timepoints. ATC code:--- | |
| Control | medium treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) cultured in standard growth medium for 2 x 24 hours, followed by culture in growth medium for another 2 hours. |
stem cell differentiation study 47 (BMP-2; TGFb; 2d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-4.7813478Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |